Trident Lifeline Ltd. · BSE:TLL
Trident Lifeline — FY2024 Earnings Presentation
31 slides from Trident Lifeline's earnings presentation, May 1, 2024
Slide 1: Cover letter to BSE: Earnings Presentation H2FY24
Date: 01st May, 2024 BSE Limited Stock ID: TLL 14th Floor, P. J. Towers, Scrip Code: 543616 Dalal Street, Fort, Mumbai – 400001. Sub: Earnings Presentation-H2FY24. Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Ear
Slide 2: FY24 Presentation
FY24 Presentation Tr i d e n t L i f e l i n e L i m i t e d May 2024
Slide 3: Inside the document
Inside the document Pg. 03 __ Company Overview Pg. 09 __ Expansive Product Portfolio Pg. 13 __ Global Footprint Pg. 17 __ Leadership Pg. 18 __ Strategy & Investment Rationale Pg. 23 __ Financials & Management Commentary
Slide 4: Company Overview
Company Overview
Slide 5: Introduction to Trident Lifeline
Introduction to Trident Lifeline About us A growing force in pharmaceutical Trident Lifeline Limited (“Trident formulations export Vision Lifeline” or “the Company”) 742 1,624 30 To be a leading is a fast-growing pharmaceutical company pharmaceutical Company with globally by providing high- quality,
Slide 6: Superior Business Model
Superior Business Model A growing force in 742 1,624 30 pharmaceutical Export market Export market product Countries present formulations products registered registrations in process in globally export Asset-light Asset-light State-of-art Strategic M&A third-party contract Contract manufacturing mod
Slide 7: Presence across Value Chain
Presence across Value Chain Procurement Manufacturing Exports Sales & Marketing Complete control over supply- • Third-party contract • Engaged in direct exports • Dedicated sales & marketing chain, procurement done by manufacturing under own brands & product team for branded sales Trident Lifeline i
Slide 8: Strengthening Presence Across Value Chain
Strengthening Presence Across Value Chain Strategic Acquisition of TNS Pharma Private Limited Commissioned Manufacturing Capacity at TNS Tablets: 30 Million 51% April 2024 Annually Total Equity Stake Acquired Commissioned Manufacturing Facility Sachin GIDC Capsules: Dry Powder Classified as a subsid
Slide 9: Strengthening Presence Across Value Chain (continued)
Strengthening Presence Across Value Chain (continued) Strategic Acquisition of Strategic Acquisition of TLL Herbal Limited Tricorp Industries Limited 51% Total Equity Stake Acquired 18% Total Equity Stake Acquired on 10th August 2023 In the business of herbal In the business of intermediates product
Slide 10: Expansive Product Portfolio
Expansive Product Portfolio
Slide 11: Expansive Product Portfolio
Expansive Product Portfolio The Company’s growing portfolio of products spans over Product categories ▸ Anti Bacterial ▸ Anti Diarrheal ▸ Anti Fungal ▸ Anti Malarial ▸ Anti Diabetic ▸ Dental Cure ▸ Proton Pump Inhibitor ▸ Anti Protozoal Product Categories 12 ▸Anti Histamine ▸Anti Hypertensive drugs
Slide 12: Expansive Product Portfolio (continued)
Expansive Product Portfolio (continued) The Company’s growing portfolio of products spans over Product categories ▸ Capsule ▸ Tablet ▸ Liquid Ointment ▸ Gel ▸ Ice Gel ▸ Mouthwash Product Categories 12 ▸ Paste ▸ Solution ▸ Suspension ▸ Toothpaste Therapeutic Categories 16 ▸ Syrup ▸ Cream 2 PRODUCT PO
Slide 13: Revenue Break-up: Product Categories
Expansive Product Portfolio (continued) Revenue Break-up: Product Categories Tablets are by far the largest product category (In %) accounting for 48% of the revenue 0 6 6 7 15 Followed by suspensions being the second largest 21 9 9 23 3 5 category which accounts for 15% of the revenue. 13 4 0 14 Ot
Slide 14: Expansive Product Portfolio (continued)
Expansive Product Portfolio (continued) 2,700+ Products in Portfolio 4 PRODUCT PORTFOLIO Trident Lifeline Limited | 13
Slide 15: Growing Global Footprint
Growing Global Footprint
Slide 16: Growing Geographical Footprint
Growing Geographical Footprint Trident Lifeline has a growing geographical footprint and a formidable presence export markets such as African, Latin American, CIS and East Asian Uzbekistan countries. Tajikistan 13 Countries where products Venezuela UAE Sudan India Myanmar Vietnam Cambodia are regist
Slide 17: Geographical Revenue Mix
Geographical Revenue Mix Being an export-oriented The share of exports • Africa is a major export market for the Other key markets for the Company, Trident has been have increased from company Company include constantly growing its export 55% in FY20 to 59% • Followed by increasing share in South •
Slide 18: Bolstering Export Growth
Bolstering Export Growth Trident Lifeline has been making Export product registrations are consistent, upfront investments in a painstaking task, involving export product registrations to significant gestation period bolster revenue growth of 1.5 to 3 years. The Company also needs to register Till d
Slide 19: Bolstering Export Growth (continued)
Bolstering Export Growth (continued) Country-wise product bifurcation Ghana, Venezuela, Cambodia (In %) & Kenya combined accounts Venezuela 504 Kuwait 39 for ~60% the total product Ghana 491 DR Congo 28 registered and under registration. Cambodia 244 Myanmar 34 Kenya 197 Others 220 192 Jordan 37 Per
Slide 20: Leadership
2 ‘c LY \ O xe) O O —I
Slide 21: Board of Directors
Board of Directors Mr. Hardik Jigishkumar Desai Mr. Shravan Harikrishna Patel Mr. Mayurkumar Mansukhbhai Gajera Mr. Hardik Jigishkumar aged 45 years is Mr. Shravan Harikrishna Patel aged 29 years is Mr. Mayurkumar Mansukhbhai Gajera aged 38 Promoter-Chairman and Executive Director of Managing Direct
Slide 22: Strategy & Investment Rationale
Strategy & Investment Rationale
Slide 23: Strategic Priorities
Strategic Priorities Continuous Expanding investments in intellectual Building sales & Strengthening Expand product product property marketing supply chain portfolio registrations registrations prowess • 300-400 additional • Registering brand’s • Strengthening strategic • Expanding dedicated • Grow
Slide 24: Investment Rationale
Investment Rationale • Trident’s business model reaps • 1,624 registrations in pipeline spread backloaded investment Extensive over 30 countries, with many benefits of product Exponential registrations under advance stages registrations product of the approval growth registrations • Current product
Slide 25: Financials & Management Commentary
Financials & Management Commentary
Slide 26: Half-Yearly Profit & Loss Snapshot
Half-Yearly Profit & Loss Snapshot (₹ in Lakh) Particulars H2FY24 H1FY24 H2FY23 YOY Change (%) +45% YOY Revenue growth in H2FY24 Total Revenue 2,742.35 1,928.38 1,889.69 45% Total Operating Expenses 2,181.77 1,462.03 1,393.72 57% EBITDA 560.58 466.35 495.97 13% EBITDA (%) 20% 24% 26% -580 BPS +13% Y
Slide 27: Management Commentary
Management Commentary • Trident Lifeline ended FY24 with superior growth in Revenue from Operations. Top line for H2FY24 stood at 2,742.35 Lakhs, registering a growth of 45% YOY. • Further, the top line for FY24 stood at 4670.72 Lakhs, registering a growth of 41% over FY23’s 3285.02 Lakhs. • Operati
Slide 28: Annual Profit & Loss Snapshot
Annual Profit & Loss Snapshot (₹ in Lakh) Particulars FY20 FY21 FY22 FY23 FY24 Total Revenue 505.63 978.12 2,237.14 3285.02 4670.72 Total Operating Expenses 517.2 836.93 1,905.94 2544.14 3643.79 EBITDA -11.57 141.2 331.2 740.88 1026.93 EBITDA (%) -2% 14% 15% 23% 22% Interest Cost 76.21 41.23 12.58 4
Slide 29: Balance Sheet Snapshot
Balance Sheet Snapshot (₹ in Lakh) Particulars FY20 FY21 FY22 FY23 FY24 Shareholders Fund -500.31 -217.21 477.57 4710.81 5296.00 Application Money Pending Allotment - - - - 99.00 Non Current Liability 646.93 457.65 148.94 392.83 1287.00 Current Liabilities 286.65 735.61 756.98 1153.40 2025.62 Other
Slide 30: Cash Flow Snapshot
Cash Flow Snapshot (₹ in Lakh) Particulars FY20 FY21 FY22 FY23 FY24 Cash from Operating Activities -81.86 -32.02 -21.47 -1900.43 222.51 Cash from Investing Activities -13.63 24.79 -44.52 -968.71 -2036.38 Cash from Financing Activities 103.75 1.43 80.19 4228.28 1100.82 Net Cash Flow 8.26 -5.8 14.20 1
Slide 31: Safe Harbour
Safe No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events Harbour not current after the